Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
The company now have a product to sell and the Govt are not going to be putting volume as their sole buying criteria. There will be a strong market (relative to normal LFT volumes, not compared with the height of the pandemic) in healthcare settings, including long term care. I'm sure Avacta will pick up business this winter. However, it aint going to change the price of fish.
Cautious. Cautious enough to post negativity almost EVERY DAY for several years, but not cautious enough to look elsewhere for somewhere to park his no doubt considerable fortune. So many words, so little to say. Gimme a break.
Currently NICE give a Quality Adjusted Life Year a value of £60K. During the pandemic government modelling put a value of £2m on a VPF, a Value of a Prevented Fatality. Remission for a young otherwise fit patient with STS would fit this definition. These numbers are for total treatment costs, not just drug values, but what price a STS treatment with a good overall response rate ?
It is not a case of cheap or expensive. The gap between the price of a course of generic dox and some form of modern targeted treatment is absolutely huge. Avacta so far as I can see have no intention of selling this cheaply, but a fair price is a lot lower than rival treatments. For one the potential demographic for 6K is not just STS patients, but a sizeable chunk of all solid tumor sufferers. Have no worries about the enormous commercial prospects here once approvals start to be gained.
Here is one for all the doubters out there. Pretty compelling argument in my book. Don't shoot the messenger BTW.
https://twitter.com/RAH00084/status/1696141773775544652
The hook is always an apparent short term weakness in the share price, and the implication that 'the market' knows something that you don't. That you run the risk of being a chump. It does not matter how feeble the argument is, it plays onto the natural fear that you are missing something and are about to be taken for a ride. AS's missed deadlines, is dox dox , what are therapeutic levels anyway, it is still years away, why hasn't it been sold yet, where are the new investors, the trial might go on for another year, AS hates private investors. I could write pages of this stuff.